Liminatus Pharma, Inc. (LIMN) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Liminatus Pharma reported revenue of $0. Net income was -$10.2M, or -$21.50 per diluted share. Operating activities generated -$10.0M of cash, leaving -$10.0M of free cash flow. At fiscal year end, Liminatus Pharma held $512,795 in total assets against $10.3M in total liabilities.
Open the full interactive Liminatus Pharma financials → Quarterly statements, key ratios, valuation history and price charts.
Liminatus Pharma Key Stats
| Share Price | $3.41 |
|---|---|
| Market Cap | $3.3M |
| 52-Week Range | $3.33 – $102.50 |
| Shares Outstanding | 967,966 (basic, 2026 Q2) |
Liminatus Pharma Income Statement
| FY 2025 | |
|---|---|
| Revenue | $0 |
| Operating Income | -$3.0M |
| Pre-Tax Income | -$10.2M |
| Net Income | -$10.2M |
| Diluted EPS | -$21.50 |
Liminatus Pharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$1.8M | -$8.5M | -$1.1M | -$1.4M |
| Diluted EPS | -$3.50 | -$0.36 | -$1.50 | -$1.50 |
Liminatus Pharma Balance Sheet
| FY 2025 | |
|---|---|
| Current Assets | $500,574 |
| Total Assets | $512,795 |
| Current Liabilities | $10.3M |
| Total Liabilities | $10.3M |
| Shareholders' Equity | -$9.8M |
Liminatus Pharma Cash Flow Statement
| FY 2025 | |
|---|---|
| Cash From Operations | -$10.0M |
| Cash From Investing | -$788,108 |
| Cash From Financing | $11.0M |
| Free Cash Flow | -$10.0M |
Figures from Liminatus Pharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Liminatus Pharma financials page for every line item.
Liminatus Pharma Company Profile
| Ticker | LIMN |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Cerritos, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001971387 |
Frequently Asked Questions
What was Liminatus Pharma's revenue in fiscal 2025?
Liminatus Pharma (LIMN) reported revenue of $0 for fiscal 2025.
What was Liminatus Pharma's net income in fiscal 2025?
Liminatus Pharma reported net income of -$10.2M for fiscal 2025.
What was Liminatus Pharma's earnings per share (EPS) in fiscal 2025?
Liminatus Pharma's diluted EPS was -$21.50 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Liminatus Pharma generate in fiscal 2025?
Liminatus Pharma generated -$10.0M of free cash flow in fiscal 2025.
What was Liminatus Pharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), Liminatus Pharma reported revenue of $0.
How many shares of Liminatus Pharma are outstanding?
Liminatus Pharma reported a weighted average of 967,966 basic shares outstanding in 2026 Q2.
What is Liminatus Pharma's market cap?
Based on its latest closing price, Liminatus Pharma (LIMN) has a market capitalization of about $3.3M.
When does Liminatus Pharma's fiscal year end?
Liminatus Pharma's fiscal year end, as registered with the SEC, is December 31.
Where is Liminatus Pharma headquartered?
Liminatus Pharma lists its business address in Cerritos, California in its SEC filings.
Liminatus Pharma Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →